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OBJECTIVEdVasculardysfunction isamajor contributor to diabetescomplications.It isalso
the primary physiologic cause of erectile dysfunction and considered an independent predictor
of cardiovascular disease (CVD) in males over age 40 years. A cohort of individuals with 50 or
more years of type 1 diabetes, Joslin Medalists, have low rates of small but not large vessel
complications. This study aims to identify the prevalence and longitudinal association of sexual
dysfunction (SD) with CVD in Joslin Medalists.
RESEARCH DESIGN AND METHODSdDescription and association of self-assessment
of SDinmalesof theMedalistcohortbyself-reportedsexualproblems withCVD.SDis validated
through the use of the abbreviated International Index of Erectile Dysfunction (IIEF).
RESULTSdOf 301 males in the Medalist Study, 69.8% reported a history of SD. Unadjusted
risk factors included elevated glycated hemoglobin (HbA1c)( P = 0.02), elevated BMI (P = 0.03),
higher total cholesterol (P = 0.02), lower HDL (P , 0.01), and increased levels of interleukin-6
(P = 0.03). SD was independently associated with CVD (age-, HbA1c-, and BMI-adjusted OR 1.9
[95% CI 1.0–3.5]). In adjusted analyses, retinal, neural, and renal complications were not asso-
ciated (P . 0.05) with SD. Current report of SD (IIEF score #17) in a subset of Medalists was
signiﬁcantly correlated with self-reported longitudinal SD.
CONCLUSIONSdSD in those with extreme-duration type 1 diabetes is independently as-
sociated with CVD, representing a large-vesselpattern. The ﬁndings suggest that SD maypredict
CVDinthosewithtype 1diabetesof longduration.Theseindividuals havealsobeenfoundto be
relatively free of microvascular complications.
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A
n increasing number of individuals
are surviving to extreme durations
of type 1 diabetes; therefore, more
individuals will be at risk for developing
related complications (1–4). The Joslin
50-YearMedalists,individualswithanav-
erage duration of 55 years of type 1 dia-
betes, have been characterized with low
levels of microvascular complications, al-
though levels of macrovascular disease
may not follow the same pattern (3,4).
Cardiovascular disease (CVD) is a leading
cause of morbidity and mortality in those
with diabetes. Multiple studies have
shown that diabetes independently in-
creases the risk for CVD up to 1.4-fold
(5–7). The primary risk factors for heart
disease associated with diabetes include
dyslipidemia, elevated BMI, poor glycemic
control, hypertension, insulin resistance,
and history of smoking (8). However, in-
dividuals with type 1 diabetes are often
leaner and have elevated HDL levels com-
pared to those with type 2 diabetes,
which, by standard risk scores, would
place them at lower risk for CVD (9,10).
For these individuals, a primary screen-
ing mechanism could be helpful for early
intervention in the development of CVD.
One proposed mechanism is screening
for sexual dysfunction (SD) and its asso-
ciated symptoms (5,11).
In this study, the relationship of
reporting “lifetime sexual problems”
with CVD in a large group of men with
extreme duration of type 1 diabetes is ex-
amined. Identifying an early marker of
CVD that a patient may be more likely
to report, such as SD, could be helpful
in interventions to alter the natural his-
tory of this disease.
RESEARCH DESIGN AND
METHODSdDetails of the Medalist
Study have been described extensively
elsewhere (3,4,12). Individuals who had
documented 50 or more years of insulin
use for type 1 diabetes were invited to
participate in the study. Informed con-
sent was obtained from all subjects prior
to participation in the study. Individuals
traveled to Joslin Diabetes Center (JDC)
(Boston,MA)forphysicalandophthalmic
examination and biospecimen collection
of urine and blood. Participants completed
questionnaires regarding medical history,
lifestyle, diet, and physical activity.
From 2005 to the time of analysis,
1,121 medals were awarded to residents
oftheUnitedStateswhodemonstrated50
ormoreyearsofinsulin-dependenttype1
diabetes. Of these Medalists, 800 partic-
ipatedinthestudy.MostMedalists(88%)
received routine endocrine care outside
JDC.The12%whodeclinedparticipation
cited illness, time commitment, or ﬁnan-
cial issues. Glycated hemoglobin (HbA1c)
was determined by high-performance liq-
uid chromatography (Tosoh G7 and 2.2,
Tokyo, Japan). Lipid proﬁles were deter-
mined by standard enzymatic methods
(kits from Roche Diagnostics, Indianapo-
lis, IN; Denka Seiken, Tokyo, Japan; and
AsahiKasei, Tokyo, Japan). Inﬂammatory
markers interleukin-6 (IL-6), plasmino-
gen activator inhibitor 1 (PAI-1), and vas-
cular celladhesionmolecule(VCAM) and
testosterone and sex hormone–binding
globulin (SHBG) levels were assayed by
human serum ELISA assays at the JDC
Specialized Assay Core (R&D Systems,
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ORIGINAL ARTICLEMinneapolis, MN; ALPCO Diagnostics,
Salem, NH). C-reactive protein (CRP)
was determined by nephelometric meth-
ods, and urine albumin-creatinine ratios
(ACRs) weredetermined byturbidimetric
methods (Quest Diagnostics, Walling-
ford, CT).
CVD status was based on self-reported
history of coronary artery disease, angina,
heart attack, prior cardiac or leg angio-
plasty, or bypass graft surgery. Renal
status was deﬁned as those with nephrop-
athy (Chronic Kidney Disease Epidemi-
ologyCollaborationformula[CKD-EPI]
estimated glomerular ﬁltration rate [eGFR]
,60 mL/min/1.73 m
2) versus those with-
out (eGFR $60 mL/min/1.73 m
2). A di-
lated eye examination was performed and
retinopathy status was graded using
guidelines from the Early Treatment Dia-
betic Retinopathy Study (ETDRS). Prolifera-
tive diabetic retinopathy (PDR) was deﬁned
asanETDRS$60(13).TheMichiganNeu-
ropathy Screening Instrument was used to
assess neuropathy; scores .2w e r ec o n s i d -
ered positive (14).
Lifetime SD was deﬁn e da sa na f ﬁr-
mative response to the question, “Please
indicate if you have ever had any sexual
problems” on a self-administered medical
history questionnaire. The ﬁve-item In-
ternational Index of Erectile Dysfunction
(IIEF) questionnaire was used to assess
current SD in a subset of the males. The
IIEF was mailed, marked only with per-
sonal study identiﬁcation number to en-
sure anonymity (15). An IIEF score #17
was considered signiﬁcant erectile dys-
function (ED).
All variables were visually inspected
and analyzed for distribution to deter-
mine the appropriate statistical methods.
Comparisons were used depending on
variable distribution (Kruskal-Wallis test,
Student t test, and x
2 [Fisher exact] test).
SD was the outcome variable used in lo-
gistic regression models examining the
relationship of both CVD and inﬂamma-
tory markers. Logistic regression was
used to estimate odds ratios (ORs) and
95% CIs and adjust for potential con-
founders, including comorbid condi-
tions and sociodemographic and lifestyle
factors.
All multivariate models were ad-
justed for age, HbA1c, and BMI. A type
1 error #0.05 was considered signiﬁ-
c a n t .A sS Dw a st h ep r i m a r yo u t c o m e ,a
multiple comparison correction was not
applied. STATA (v12 SE, College Sta-
tion, TX) and SAS (v9.2, Cary, NC)
were used.
RESULTSdOf all Medalists, 48.7%
(n = 320) were male and 301 answered
the question regarding a history of sex-
ual problems; 69.8% of males reported
experiencing SD over their lifetime.
These individuals had a mean age, age at
diagnosis, and duration of diabetes of
71.7 6 8.5 years, 12.4 6 7.0 years, and
59.3 6 7.3 years, respectively. Mean BMI
was 25.8 6 3.6 kg/m
2, with mean insulin
dose 0.49 6 0.2 units/kg
2. Mean HbA1c
was 7.03% 6 0.89 (53 6 6 mmol/mol).
The lipid proﬁle included a mean choles-
terol of 152.0 6 31.7 mg/dL, with HDL
57.3 6 17.2 mg/dL and LDL 79.5 6 22.8
mg/dL. Mean ACR was 28.3 6 68.3
mg/mg, with 49.3% having PDR and
51.8% of males having CVD (Table 1).
Among those with and without SD,
age, ageatdiagnosis, andduration of type
1 diabetes were not signiﬁcantly different
(P = 0.93, P = 0.61, and P = 0.69, respec-
tively) (Table 1). Mean BMI (26.1 6 3.8
vs. 25.16 3.0kg/m
2) was higher in those
reporting SD (P = 0.03), as were ever
smoking (51.7 vs. 39.3%, P = 0.05) and
HbA1c (P = 0.02). Total cholesterol levels
were signiﬁcantly higher (159.3 6 32.1
vs. 150.1 6 30.6 mg/dL, P = 0.02), and
HDL levels (55.1 6 16.2 vs. 62.1 6 17.8
mg/dL,P,0.01)weresigniﬁcantlylower
in those without SD. The percentage of
those with PDR was slightly higher in
Medalists reporting SD (54.0 vs. 39.1%,
P = 0.04); however, no relationship was
found with neuropathy (P = 0.23). Of
those males without SD, 44.3% had
CVD, compared with 56.5% with SD
(P = 0.05) (Table 1).
LevelsofIL-6(median[Q1–Q3]:0.09
pg/mL [0.04–0.19] vs. 0.1 pg/mL [0.06–
0.3],P=0.03)weresigniﬁcantlyhigherin
those reporting SD. Other inﬂammatory
markers, including PAI-1 and CRP, were
notsigniﬁcantlydifferentbetweengroups
(P=0.08andP=0.45).Totaltestosterone
and SHBG did not vary between those
with and without SD (P =0 . 9a n dP =
0.3) (Table 2).
There was a signiﬁcant difference in
the use of lipid-lowering agents (57.1%
noSDvs.74.3%SD,P=0.003)andplate-
let medications (23.1% no SD vs. 35.2%
SD, P = 0.04) but not in the use of blood
pressure medication or adrenergic, b,o r
calcium channel blockers (Supplemen-
tary Table 1). Use of phosphodiesterase
type 5 (PDE5) inhibitors was reported as
1.8% tadalaﬁl, 2.5% sildenaﬁl, and 0.7%
vardenaﬁl; penile implants were reported
by 3.6% (Supplementary Table 2). There
was no relationship between insulin
pump use or current self-rated blood glu-
cose control (P . 0.05) and SD. There
Table 1dClinical characteristics of male Medalists by SD status
Overall
(n = 301)
No dysfunction
(n =9 1 )
Dysfunction
(n = 210) P
Age (years) 71.7 6 8.5 71.6 6 9.1 71.7 6 8.2 0.93
Age at diagnosis (years) 12.4 6 7.0 12.0 6 7.0 12.4 6 7.0 0.61
Duration (years) 59.3 6 7.3 59.6 6 7.9 59.2 6 7.1 0.69
BMI (kg/m
2) 25.8 6 3.6 25.1 6 3.0 26.1 6 3.8 0.03
Smoking (ever) (%) 48.0 39.3 51.7 0.05
HbA1c (%) 7.0 6 0.9 6.8 6 0.8 7.1 6 0.9 0.02
HbA1c (mmol/mol) 53.0 6 6.8 51.0 6 6.0 54.0 6 6.8 0.02
Insulin dose (units/kg
2)0 . 4 9 6 0.18 0.48 6 0.18 0.50 6 0.20 0.41
Systolic BP (mmHg) 126.2 6 12.8 123.6 6 13.5 127.3 6 12.7 0.07
Diastolic BP (mmHg) 66.3 6 8.2 65.6 6 8.7 67.1 6 7.5 0.23
Cholesterol (mg/dL) 152.0 6 31.7 150.1 6 30.6 159.3 6 32.1 0.02
HDL (mg/dL) 57.3 6 17.2 62.1 6 17.8 55.1 6 16.2 ,0.01
LDL (mg/dL) 79.5 6 22.8 79.7 6 22.2 79.2 6 23.2 0.87
Triglycerides (mg/dL) 79.1 6 43.8 80.6 6 47.2 79.0 6 43.3 0.77
Hypertension (%) 71.4 67.0 75.7 0.12
CVD (%)* 51.8 44.3 56.5 0.05
PDR (%) (ETDRS .60)x 49.3 39.1 54.0 0.04
ACR (mg/mg) 28.3 6 68.3 24.5 6 62.5 26.7 6 62.0 0.5
Neuropathy (%) 48.9 43.1 51.6 0.23
(MNSI .2)
Data are presented as mean 6 SD or %. MNSI, Michigan Neuropathy Screening Instrument. *History of
coronary artery disease, angina, MI, cardiac/leg angioplasty, or bypass graft surgery. xThis relationship is no
longer signiﬁcant with adjustment for antihypertensives.
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Turek and Associateswas also no relationship with the num-
ber of times a day blood sugars were
checked, level of education, or self-
rated quality of life (P . 0.05) (Supple-
mentary Table 3).
The ﬁve-item IIEF questionnaire was
completed and returned by a subset of
63% (n = 197) of males, with 85.3%
reporting a signiﬁcant degree of ED
(IIEF score $17), in agreement with the
original self-report question (x
2 = 256.0,
P , 0.001) (15). Demographic and ba-
sic clinical characteristics did not vary
signiﬁcantly between the subsets of
men who did and did not complete the
IIEF.
Male Medalists with CVD (51.8%)
were older and had a longer type 1 di-
abetes duration than males without CVD
(73.3 6 8.5 vs. 70.0 6 8.0 years [P =
0.005] and 60.5 6 7.8 vs. 57.9 6 6.4
years [P = 0.003], respectively), as well
as higher HbA1c (7.2 6 0.9 vs. 6.9 6
0.8%; 55 6 6.8 vs. 52 6 6 mmol/mol
[P = 0.002]). Individuals with CVD had
higher total cholesterol, higher LDL, and
higherHDLthanthosewithoutCVD(P,
0.01). Males with CVD had a lower
mean eGFR (61.7 6 19.7 vs. 72.7 6 18.7
mL/min/1.73 m
2 [P , 0.001]) and higher
rate of PDR (61.3 vs. 37.2%, P , 0.001).
There was no difference in inﬂammatory
markers, including CRP, IL-6, PAI-1, or
VCAM, between those with and without
CVD (P . 0.05) (Table 3). There was no
signiﬁcant difference in the use of PDE5 in-
hibitors by CVD disease; however, the fre-
quency of men with a penile implant who
have CVD (80 vs. 20%, P = 0.04) is higher
than those without CVD.
The association of lifetime SD and
CVD remained with adjustment for age,
BMI, cholesterol, HDL, smoking, IL-6,
antihypertensive medication, and HbA1c
(OR 3.7 [95% CI 1.5–9.0]). Additionally,
lower inﬂammatory levels of IL-6 are as-
sociated with protection from reporting
SD (0.4 [0.2–0.95]) when adjusted for
age, BMI, HDL, smoking, and HbA1c.
CONCLUSIONSdSeveral studies
have established the connection between
ED and CVD in men starting the fourth
decade of life (11,16–18). The hypothe-
sized etiology is that vessels feeding the
penis are smaller than those feeding the
heart and therefore show clinical symp-
toms earlier. The physiologic mechanism
is endothelial dysfunction resulting from
the inhibition of the nitric oxide cascade,
thus preventing dilation of the arteries
impairing the blood ﬂow imperative for
rigidity (19). The etiology of endothelial
dysfunctionmay bedifferent, orsynergis-
tic, depending on endogenous risk be-
tween those with and without diabetes
due to the inherent damaging effects of
the hyperglycemic exposure. Importantly
for type 1 diabetic patients, this relation-
ship may be independent of previously
identiﬁed risk factors for CVD, as used
in the Framingham Index (20). This is
supported by the independent relation-
ship of CVD and SD from other risk fac-
tors, including age and BMI, among this
groupofextreme-durationtype1diabetic
patients.
The 50-Year Medalists are a group of
individuals who have had type 1 diabetes
for 50 or more years and resultant pro-
longedhyperglycemicexposure.Anonset
of diabetes in the early to middle part of
the last century meant that blood glucose
management consisted of weekly testing
with once-daily injections, resulting in
frequent bouts of diabetic ketoacidosis or
hypoglycemia and the potential for sig-
niﬁcant endothelial damage. Previous lit-
erature on Medalists documented a lower
than expected prevalence of microvas-
cular complications, including PDR
(50.6%), neuropathy (60.6%), and ne-
phropathy(13.1%)(3,4,12,21–24).Asre-
ported, the prevalence of CVD among
male Medalists is 51.8%. At an index age
of 75 years, in the Framingham Health
Study, the adjusted lifetime(up to95years
ofage)riskestimateformenis54.5%(95%
CI 52.2–56.9), demonstrating that there is
no increased prevalence of CVD among
Medalists (10). This is in contrast to the
ancillary study of the Epidemiology of
Diabetes Interventions and Control
(uroEDIC) Study on urologic symptoms,
which assessed the prevalence of SD
among their participants who had a mean
type 1 diabetes duration of 22.1 years, av-
erage age of 44.6 6 6.6 years, and time-
weighted average HbA1c of 8.07%, ﬁnding
an overall prevalence of 58% ED (IIEF 0–
20); they did not assess correlation with
CVD (25). Our ﬁnding of no difference in
testosterone levels in those with SD is con-
sistent with the ﬁndings of Van Den Edeen
et al. (25).
Klein et al. (26) in the Wisconsin Ep-
idemiologyStudyofDiabeticRetinopathy
examined markers of SD and found a cu-
mulative incidence of 25% in men 21
yearsofageorolderwith10ormoreyears
of type 1 diabetes (mean age 34.4 6 8.4
years and duration 20.5 6 7.0 years) and
mean HbA1c of 9.7%. Those 40 years of
age and older had the highest overall in-
cidence at 48.6%. Primary risk factors
otherthanageinthispopulationincluded
untreated hypertension (OR 5.0 [95% CI
2.05–12.3]) and smoking status (current
OR 2.4 [1.09–5.30])destablished risk
factorsforCVD.Nosigniﬁcantrelationship
was found with microvascular complica-
tions with adjustment for age, smoking,
and untreated hypertension. No contem-
porary association was found with CVD;
however, total cholesterol was associated
with SD but not HDL (26). In similarly
aged nondiabetic men, the Massachusetts
Male Aging Study documented a complete
impotencerateof67%by70years,andthe
NationalHealthandNutritionExamination
Survey (NHANES) reported a prevalence of
77.5% for those 75 years of age and older
(27,28).
In this study, we examined preva-
lence of SD and its relationship to CVD. A
limitationof theself-reporting of“lifetime
sexual problems” is that it may capture
those with a history of SD due to social,
economic, or lifestyle factors instead
of progressive endothelial pathology,
whichmayprecedelarger-vesseldisease.
Close agreement of SD with IIEF scores
suggests that the SD question may be
capturing ED in our sample. Addition-
ally, the IIEF cutoff was associated with
cardiovascular risk factors, as well as
CVD, the outcome of interest. Neuro-
genic, pharmacologic, and quality of
lifefactorsdidnotconfoundorinﬂuence
the observed association of IIEF scores
and CVD.
Table 2dLaboratory characteristics of male Medalists by SD status
Overall No dysfunction Dysfunction P
Total testosterone
(ng/mL) 3.2 6 2.6 3.1 6 2.2 3.2 6 2.6 0.9
SHBG (nmol/L) 64.8 6 33.6 68.1 6 38.3 62.7 6 29.7 0.3
PAI-1 (pg/mL) 169.0 (106.2–229.7) 160.0 (99.0–203.5) 204.1 (106.4–246.5) 0.08
IL-6 (pg/mL) 0.12 (0.06–0.24) 0.09 (0.04–0.19) 0.1 (0.06–0.3) 0.03
CRP (mg/L) 3.3 6 11.5 0.94 6 5.1 1.03 6 13.7 0.45
Data are presented as mean 6 SD or median (Q1–Q3).
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Sexual dysfunction after 50 years of type 1 diabetesDuration, glycemic control, age, and
lipid proﬁle did not correlate with micro-
vascular complications; however, CVD
showed a signiﬁcant relationship with
HbA1c, age, duration, lipid proﬁle, and
inﬂammatorymarkers.Instudiesofthose
with type 2 diabetes, the relationship of
ED and CVD is thought to begin with the
damagecausedbythemilieuofmetabolic
changes associated with the metabolic
syndrome, established as a direct prede-
cessor of CVD (29–33). However, as the
Medalists do not have the same lipid pro-
ﬁle (total cholesterol levels ,200 mg/dL,
HDLlevels.35mg/dL,and atriglyceride
level ,70 mg/dL), increased weight, and
insulin resistance characteristic of type 2
diabetes (insulin dose, 0.5 units/kg
[0.37–0.57]), the same early warning
s i g n sf o rC V Da r en o tp r e s e n t .O ft h e
Medalists who have died, 58.6% died of
CVD, demonstrating a signiﬁcant mortal-
ity from this disease risk that necessitates
early detection (29–33). Findings of this
analysis indicate that history of SD pro-
vides an important screening tool in the
absenceofthetypicalriskproﬁleofglycemic
control, BMI, and dyslipidemia in patients
with type 1 or type 2 diabetes.
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LDL (mg/dL) 83.8 6 23.3 (147) 75.0 6 21.0 (157) 0.001
Triglycerides (mg/dL) 78.2 6 41.8 (147) 81.4 6 46.6 (158) 0.52
Testosterone (ng/mL) 3.1 6 2.8 (113) 3.3 6 2.4 (130) 0.61
SHBG (nmol/L) 66.0 6 30.3 (86) 64.4 6 35.6 (120) 0.74
EPI eGFR (mL/min/1.73 m
2)7 2 . 7 6 18.7 (146) 61.7 6 19.7 (158) ,0.001
ACR (mg/mg) 24.5 6 47.8 (130) 31.8 6 82.9 (141) 0.38
Microalbuminuria (%) 13.9 (18) 14.9 (21) 0.8
PDR (%) 37.2 (42) 61.3 (65) ,0.001
Neuropathy (%) 48.3 (55) 47.9 (57) 0.96
Inﬂammatory markers
PAI-1 (pg/mL) 190.4 (124.5–242.3) (65) 155.5 (95.0–197.4) (73) 0.35
IL-6 (pg/mL) 0.12 (0.05–0.22) (53) 0.12 (0.05–0.3) (67) 0.6
CRP (mg/L) 0.9 (0.5–1.8) (144) 1.1 (0.5–2.9) (153) 0.12
VCAM (ng/mL) 1,833.4 6 105.7 (64) 2,034.33 6 924.6 (76) 0.27
Medication use
Blood pressure drug 42.6 (83) 57.4 (112) 0.01
Adrenergic blocker 40.0 (2) 60.0 (3) 0.7
b-Blocker 22.6 (23) 77.5 (79) ,0.001
Calcium channel blocker 42.6 (26) 57.4 (35) 0.33
Lipid-lowering drug 40.4 (86) 59.6 (127) ,0.001
Data are presented as mean 6 SD, % (n), or median (Q1–Q3).
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